Device Start-Ups Inch Closer To Elusive Epilepsy Treatment

Despite the availability of more than 20 anti-epilepsy drugs, surgery, and a neurostimulation therapy that’s been available for 15 years, a large proportion of the three million patients in the US with epilepsy continue to have seizures. Emerging device companies aim to provide a solution for them.

Many people with epilepsy live with the constant risk of having a seizure. At any moment a seizure might force them to the ground or cause them to zone out, possibly behind a desk or a steering wheel. They go to bed each night knowing there’s a risk, albeit a small one, that they won’t wake up in the morning. For people whose seizures are not controlled by drug therapies – approximately one million of the three million people in the US with epilepsy (more than 60 million people worldwide), every day is a series of risk-benefit analyses that would be unthinkable to most of us. Even though I have been seizure-free for a year, should I drive? Will I have a seizure while giving the baby a bath? Can I scuba dive? Today’s top blog post on the Epilepsy Therapy Project (www.epilepsy.com

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

Opportunity For Medtech To Contribute To EU Cybersecurity Recommendations

 

The deadline for comments is 30 June 2025

Dexcom Wins FDA Nod For 15-Day G7 CGM, Closing Gap With Abbott’s 14-Day FreeStyle Libre

 
• By 

Dexcom announced it received US clearance for its 15-day CGM, which has a MARD of 8.0% and is expected to launch in the second half of 2025 to allow for integration with insulin pumps.

Diagnostics Are Essential, But How Can Companies Ensure A Fair Price?

 

Biotech and pharma are increasingly clear about one thing: They need diagnostics. But with prices suppressed, how have diagnostics companies proven their utility without going under?